Simcere Pharmaceutical Buys Stake In Antitumor Firm
This article was originally published in PharmAsia News
Executive SummarySimcere Pharmaceutical has announced that it is paying 64.82 million yuan ($9.2 million) to buy 70 percent stake in Anhui Zhongren Pharmaceutical, its third acquisition since listing in the U.S. last year. Anhui Zhongren specializes in the production of antitumor implant agents and is the developer of an innovative sustained-release fluorouracil implant that is unique in the market. One of Simcere's key strategies is to concentrate on core product acquisition and expansion; its latest purchase will enrich the firm's antitumor product portfolio as well as consolidate its leading position in the field. Company officials disclosed that some 800 million yuan ($114 million) has been allocated for future acquisitions. (Click here for more - Chinese language)
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.